Aktienanalyse zu Orchestra Biomed Holdings Inc (OBIO)OBIOOrchestra Biomed Holdings Inc

Orchestra BioMed Holdings, Inc. is a biomedical innovation company. The Company’s lead product candidates include Atrioventricular Interval Modulation (AVIM) therapy for the treatment of hypertension (HTN), the leading risk factor for death worldwide and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The Company develops bioelectronic therapies based on patented Cardiac Neuromodulation Therapy (CNT) technology. The AVIM is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Its Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Orchestra Biomed Holdings Inc (OBIO) is a good buy right now due to its current price of $5.59, which is significantly below the average analyst price target of $10, suggesting a potential upside of approximately 79%. The stock has shown a year-to-date change of +29.70%, indicating positive momentum. However, the main risk is its high net loss, which reached $24.08 million in Q2 2026, reflecting ongoing financial challenges.